nach oben

European Archives of Psychiatry and Clinical Neuroscience

Erschienen in:

11.01.2019 | Invited Review

Understanding the evidence for medical cannabis and cannabis-based medicines for the treatment of chronic non-cancer pain

verfasst von: Gabrielle Campbell, Emily Stockings, Suzanne Nielsen

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

The use of medical cannabis and cannabis-based medicines has received increasing interest in recent years; with a corresponding surge in the number of studies and reviews conducted in the field. Despite this growth in evidence, the findings and conclusions of these studies have been inconsistent. In this paper, we outline the current evidence for medical cannabis and cannabis-based medicines in the treatment and management of chronic non-cancer pain. We discuss limitations of the current evidence, including limitations of randomised control trials in the field, limits on generalisability of previous findings and common issues such as problems with measurements of dose and type of cannabinoids. We discuss future directions for medicinal cannabinoid research, including addressing limitations in trial design; developing frameworks to monitor for use disorder and other unintended outcomes; and considering endpoints other than 30% or 50% reductions in pain severity.

National Academies of Sciences Engineering and Medicine (2017) The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. The National Academies Press, Washington, DC

Hauser W, Fitzcharles MA, Radbruch L, Petzke F (2017) Cannabinoids in pain management and palliative medicine. Deutsch Arztebl Int 114(38):627–634

Whiting PF, Wolff RF, Deshpande S et al (2015) Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 313(24):2456–2473CrossRefPubMed

Petzke F, Enax-Krumova EK, Hauser W (2016) Efficacy, tolerability and safety of cannabinoids for chronic neuropathic pain: a systematic review of randomized controlled studies. Schmerz (Berlin Germany) 30(1):62–88CrossRef

Stockings E, Campbell G, Hall WD et al (2018) Cannabis and cannabinoids for the treatment of people with chronic non-cancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain

Aviram J, Samuelly-Leichtag G (2017) Efficacy of cannabis-based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials. Pain Phys 20(6):E755–E796

Mücke M, Phillips T, Radbruch L, Petzke F, Hauser W (2018) Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev 3:CD012182PubMed

Hauser W, Finn DP, Kalso E et al (2018) European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. Eur J Pain (London England) 22(9):1547–1564CrossRef

Hauser W, Petzke F, Fitzcharles MA (2018) Efficacy, tolerability and safety of cannabis-based medicines for chronic pain management—an overview of systematic reviews. Eur J Pain (London England) 22(3):455–470CrossRef

10.

Allan GM, Finley CR, Ton J et al (2018) Systematic review of systematic reviews for medical cannabinoids: pain, nausea and vomiting, spasticity, and harms. Can Fam Phys (Med Fam Can) 64(2):e78–e94

11.

Deshpande A, Mailis-Gagnon A, Zoheiry N, Lakha SF (2015) Efficacy and adverse effects of medical marijuana for chronic noncancer pain: systematic review of randomized controlled trials. Can Fam Phys 61(8):e372–e381

12.

International Association for the Study of Pain (IASP) (2018) IASP terminology. http://www.iasp-pain.org/terminology?navItemNumber=576#Neuropathicpain. Accessed 30 July 2018

13.

Nugent SM, Morasco BJ, O’Neil ME et al (2017) The effects of cannabis among adults with chronic pain and an overview of general harms: a systematic review. Ann Intern Med 167(5):319–331PubMedCrossRef

14.

Walitt B, Klose P, Fitzcharles MA, Phillips T, Hauser W (2016) Cannabinoids for fibromyalgia. Cochrane Database Syst Rev 7:CD011694PubMed

15.

Allan GM, Ramji J, Perry D et al (2018) Simplified guideline for prescribing medical cannabinoids in primary care. Can Fam Phys (Med Fam Can) 64(2):111–120

16.

Nielsen S, Germanos R, Weier M et al (2018) The use of cannabis and cannabinoids in treating symptoms of multiple sclerosis: a systematic review of reviews. Curr Neurol Neurosci Rep 18(2):8PubMedCrossRef

17.

Malik Z, Baik D, Schey R (2015) The role of cannabinoids in regulation of nausea and vomiting, and visceral pain. Curr Gastroenterol Rep 17(2):9CrossRef

18.

Kerlin AM, Long M, Kappelman M, Martin C, Sandler RS (2018) Profiles of patients who use marijuana for inflammatory bowel disease. Digest Dis Sci 63(6):1600–1604PubMedCrossRef

19.

de Vries M, van Rijckevorsel DCM, Vissers KCP, Wilder-Smith OHG, van Goor H (2017) Tetrahydrocannabinol does not reduce pain in patients with chronic abdominal pain in a phase 2 placebo-controlled study. Clin Gastroenterol Hepatol 15(7):1079–86.e4PubMedCrossRef

20.

de Vries M, Van Rijckevorsel DC, Vissers KC, Wilder-Smith OH, Van Goor H (2016) Single dose delta-9-tetrahydrocannabinol in chronic pancreatitis patients: analgesic efficacy, pharmacokinetics and tolerability. Br J Clin Pharmacol 81(3):525–537PubMedPubMedCentralCrossRef

21.

Kafil TS, Nguyen TM, MacDonald JK, Chande N (2018) Cannabis for the treatment of ulcerative colitis. Cochrane Database Syst Rev 11(2):CD012954PubMed

22.

Walitt B, Klose P, Fitzcharles MA, Phillips T, Häuser W (2016) Cannabinoids for fibromyalgia. Cochrane Database Syst Rev 7:CD011694PubMed

23.

Skrabek RQ, Galimova L, Ethans K, Perry D (2008) Nabilone for the treatment of pain in fibromyalgia. J Pain 9(2):164–173CrossRefPubMed

24.

Blake DR, Robson P, Ho M, Jubb RW, McCabe CS (2006) Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 45(1):50–52PubMedCrossRef

25.

Pinsger M, Schimetta W, Volc D, Hiermann E, Riederer F, Pölz W (2006) Nutzen einer add-on-therapie mit dem synthetischen cannabinomimetikum nabilone bei patienten mit chronischen Schmerzzuständen—eine randomisierte kontrollierte studie. Wien Klin Wochenschr 118(11):327–335PubMedCrossRef

26.

National Academies of Sciences, Engineering, and Medicine (2017) The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. National Academies Press, Washington

27.

Campbell G, Nielsen S, Bruno R et al (2015) The Pain and Opioids IN Treatment study: characteristics of a cohort using opioids to manage chronic non-cancer pain. Pain 156(2):231–242CrossRefPubMed

28.

Rogers KD, Kemp A, McLachlan AJ, Blyth F (2013) Adverse selection? A multi-dimensional profile of people dispensed opioid analgesics for persistent non-cancer pain. PLoS ONE 8(12):e80095PubMedPubMedCentralCrossRef

29.

Tunks ER, Crook J, Weir R (2008) Epidemiology of chronic pain with psychological comorbidity: prevalence, risk, course, and prognosis. Can J Psychiatry 53(4):224–234PubMedCrossRef

30.

Walker ER, Druss BG (2017) Cumulative burden of comorbid mental disorders, substance use disorders, chronic medical conditions, and poverty on health among adults in the U.S.A. Psychol Health Med 22(6):727–735PubMedCrossRef

31.

Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W (2018) Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev 3:CD012182PubMed

32.

Dechartres A, Trinquart L, Boutron I, Ravaud P (2013) Influence of trial sample size on treatment effect estimates: meta-epidemiological study. BMJ Br Med J 346:f2304CrossRef

33.

Hauser W, Fitzcharles MA (2018) The perils of overestimating the efficacy of cannabis-based medicines for chronic pain management. Pain Phys 21(1):E79–E80

34.

Vos T, Barber RM, Bell B et al (2016) Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386(9995):743–800CrossRef

35.

Lynch ME, Ware MA (2015) Cannabinoids for the treatment of chronic non-cancer pain: an updated systematic review of randomized controlled trials. J Neuroimmune Pharmacol 10(2):293–301PubMedCrossRef

36.

Bhatt DL, Mehta C (2016) Adaptive designs for clinical trials. N Engl J Med 375(1):65–74CrossRefPubMed

37.

Turk DC, Dworkin RH, Allen RR et al (2003) Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain 106(3):337–345PubMedCrossRef

38.

Levy N, Sturgess J, Mills P (2018) “Pain as the fifth vital sign” and dependence on the “numerical pain scale” is being abandoned in the US: why? Br J Anaesth 120(3):435–438PubMedCrossRef

39.

Piper BJ, Beals ML, Abess AT et al (2017) Chronic pain patients’ perspectives of medical cannabis. Pain 158(7):1373–1379PubMedPubMedCentralCrossRef

40.

Campbell G, Hall WD, Peacock A et al (2018) Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. Lancet Public Health 3(7):e341–e350PubMedPubMedCentralCrossRef

41.

Wilsey B, Deutsch R, Marcotte TD (2016) Maintenance of blinding in clinical trials and the implications for studying analgesia using cannabinoids. Cannabis Cannabinoid Res 1(1):139–148PubMedPubMedCentralCrossRef

42.

Ware MA, Fitzcharles M-A, Joseph L, Shir Y (2010) The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg 110(2):604–610PubMedCrossRef

43.

Colagiuri B (2010) Participant expectancies in double-blind randomized placebo-controlled trials: potential limitations to trial validity. Clin Trials 7(3):246–255PubMedCrossRef

44.

Goldstein RB, Chou SP, Smith SM et al (2015) Nosologic comparisons of DSM-IV and DSM-5 alcohol and drug use disorders: results from the national epidemiologic survey on alcohol and related conditions-III. J Stud Alcohol Drugs 76(3):378–388PubMedPubMedCentralCrossRef

45.

Mewton L, Slade T, Teesson M (2013) An evaluation of the proposed DSM-5 cannabis use disorder criteria using Australian National Survey Data. J Stud Alcohol Drugs 74(4):614–621PubMedCrossRef

46.

Hall W (2015) What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? Addiction 110(1):19–35PubMedCrossRef

47.

Morasco BJ, Gritzner S, Lewis L, Oldham R, Turk DC, Dobscha SK (2011) Systematic review of prevalence, correlates, and treatment outcomes for chronic non-cancer pain in patients with comorbid substance use disorder. Pain 152(3):488–497PubMedCrossRef

48.

Turk DC, O’Connor AB, Dworkin RH et al (2012) Research design considerations for clinical studies of abuse-deterrent opioid analgesics: IMMPACT recommendations. Pain 153(10):1997–2008PubMedPubMedCentralCrossRef

49.

Gourlay DL, Heit HA, Almahrezi A (2005) Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med 6(2):107–112PubMedCrossRef

50.

Schuermeyer J, Salomonsen-Sautel S, Price RK et al (2014) Temporal trends in marijuana attitudes, availability and use in Colorado compared to non-medical marijuana states: 2003–11. Drug Alcohol Depend 140:145–155

51.

Troutt WD, DiDonato MD (2015) Medical cannabis in Arizona: patient characteristics, perceptions, and impressions of medical cannabis legalization. J Psychoact Drugs 47(4):259–266CrossRef

52.

Krcevski-Skvarc N, Wells C, Hauser W (2018) Availability and approval of cannabis-based medicines for chronic pain management and palliative/supportive care in Europe: a survey of the status in the chapters of the European Pain Federation. Eur J Pain 22(3):440–454CrossRefPubMed

53.

Nielsen S, Sabioni P, Trigo J et al (2017) Opioid-sparing effects of cannabinoids: a systematic review and meta-analyses. Neurospychopharmacology 49(9):1752–1765CrossRef

54.

Bachhuber MA, Saloner B, Cunningham CO, Barry CL (2014) Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Intern Med 174(10):1668–1673PubMedPubMedCentralCrossRef

55.

Bradford AC, Bradford W, Abraham A, Bagwell Adams G (2018) Association between us state medical cannabis laws and opioid prescribing in the medicare part D population. JAMA Intern Med

56.

Livingston MD, Barnett TE, Delcher C, Wagenaar AC (2017) Recreational cannabis legalization and opioid-related deaths in Colorado, 2000–2015. Am J Public Health 107(11):1827–1829PubMedCrossRefPubMedCentral

57.

Pardo B (2017) Do more robust prescription drug monitoring programs reduce prescription opioid overdose? Addiction 112(10):1773–1783PubMedCrossRef

58.

Abuhasira R, Schleider LB, Mechoulam R, Novack V (2018) Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. Eur J Intern Med 49:44–50PubMedCrossRef

59.

Boehnke KF, Litinas E, Clauw DJ (2016) Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. J Pain 17(6):739–744CrossRefPubMed

60.

Corroon JM Jr, Mischley LK, Sexton M (2017) Cannabis as a substitute for prescription drugs—a cross-sectional study. J Pain Res 10:989PubMedPubMedCentralCrossRef

61.

Haroutounian S, Ratz Y, Ginosar Y et al (2016) The effect of medicinal cannabis on pain and quality-of-life outcomes in chronic pain: a prospective open-label study. Clin J Pain 32(12):1036–1043PubMedCrossRef

62.

Campbell G, Hall W, Nielsen S (2018) What does the ecological and epidemiological evidence indicate about the potential for cannabinoids to reduce opioid use and harms? A comprehensive review. Int Rev Psychiatry (in press, accepted 6 Aug 2018)

63.

Klieger SB, Gutman A, Allen L, Pacula RL, Ibrahim JK, Burris S (2017) Mapping medical marijuana: state laws regulating patients, product safety, supply chains and dispensaries, 2017. Addiction 112(12):2206–2216PubMedPubMedCentralCrossRef

64.

Dowell D, Haegerich TM, Chou R (2016) CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA 315(15):1624–1645PubMedPubMedCentralCrossRef

65.

NSW Health (2018) Chronic pain management: information for medical practitioners. https://www.health.nsw.gov.au/pharmaceutical/doctors/Pages/chronic-pain-medical-practitioners.aspx. Accessed 29 Oct 2018

66.

Oliveira CB, Maher CG, Pinto RZ et al (2018) Clinical practice guidelines for the management of non-specific low back pain in primary care: an updated overview. Eur Spine J 27(11):2791–2803CrossRefPubMed

67.

Häuser W, Fitzcharles M-A, Radbruch L, Petzke F (2017) Cannabinoids in pain management and palliative medicine. Dtsch Arztebl Int 114(38):627–634PubMedPubMedCentral

Titel: Understanding the evidence for medical cannabis and cannabis-based medicines for the treatment of chronic non-cancer pain
verfasst von: Gabrielle Campbell
Emily Stockings
Suzanne Nielsen
Publikationsdatum: 11.01.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 1/2019
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-018-0960-9

Neu im Fachgebiet Psychiatrie

18.04.2024 | Arterielle Hypertonie | Nachrichten

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Understanding the evidence for medical cannabis and cannabis-based medicines for the treatment of chronic non-cancer pain

Abstract

Neu im Fachgebiet Psychiatrie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Delir kann Demenz begünstigen

Zunahme von Geschlechtsinkongruenz und -dysphorie registriert

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Psychiatrie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

New trends in cannabis potency in USA and Europe during the last decade (2008–2017)

How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review

An update on cannabis use disorder with comment on the impact of policy related to therapeutic and recreational cannabis use

Does regular cannabis use affect neuroanatomy? An updated systematic review and meta-analysis of structural neuroimaging studies

Cannabis and mental illness: a review

A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects

Neu im Fachgebiet Psychiatrie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Delir kann Demenz begünstigen

Zunahme von Geschlechtsinkongruenz und -dysphorie registriert

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Psychiatrie